Premium
P2‐265: THE CLINICAL CHARACTERISTICS OF COGNITIVE IMPAIRMENT IN PATIENTS WITH SMALL VESSEL DISEASE
Author(s) -
Yuan Junliang
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.2672
Subject(s) - stroop effect , montreal cognitive assessment , neuropsychology , hyperintensity , psychology , audiology , frontal lobe , medicine , cognition , temporal lobe , cognitive impairment , cardiology , magnetic resonance imaging , psychiatry , radiology , epilepsy
both N-Brev and Brev-A were detected in serum of demented and NDCs. A general increase in N-Brev levels (p1⁄40.05) was observed in 28 AD patients compared to 41 patients of OD while Brev-A levels were decreased (p1⁄40.04). N-Brev levels were decreased in OD compared to 48 NDCs (p<0.01) while Brev-A levels were higher (p1⁄40.01). N-Brev/Brev-A ratio was high in AD compared to OD (p<0.01) as well as in NDCs compared to OD (p<0.0001). No differences were observed between AD and NDCs. Conclusions: We developed the first assays detecting the N-terminal of brevican as well as an ADAMTS4-cleaved fragment of this protein in blood. The most important finding of this study is the detection and quantification of this CNS protein in blood. This permits the possibility of gaining information on the pathology underlying CNS diseases using only a blood sample. The differential biomarker levels between AD and OD allows the possibility that N-Brev and Brev-A may distinguish between different forms of dementia.